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Abstract
Background: Telephone-based smoking cessation services (‘quitlines’) are both effective and cost-effective.
Knowledge of modifiable baseline factors in real-life settings with heterogeneous participants is essential for the
development and improvement of treatment protocols to assist in telephone-based smoking cessation. The aim
was to assess if self-perceived abilities to cope measured at baseline, would predict abstinence at the 12-month
follow-up at the Swedish National Tobacco Quitline (SNTQ).
Methods: The data were retrieved from a previous randomized controlled trial comparing the effectiveness of
proactive and reactive service at the SNTQ. Included were 612 clients calling the SNTQ between February 2009 and
September 2010. Outcome measures were self-reported point prevalence and 6-month continuous abstinence at
the 12-month follow-up. Plausible predictors of smoking cessation were assessed at the first call and in a baseline
questionnaire. Self-perceived abilities at baseline were measured by two questions: (1) How likely is it that you will
be smoke-free in one year? and (2) How likely are you to be able to handle stress and depressive mood without
smoking? The associations between potential predictors and outcome (smoke-free at 12-month follow-up) were
assessed by logistic regression analysis.
Results: Of the two potential predictors for abstinence at 12-month follow-up, only the perceived ability to handle
stress and depressive mood without smoking remained significant in the adjusted analyses (Odds Ratio, OR 1.13,
95% CI 1.00–1.27 for point prevalence and OR 1.16, 95% CI 1.01–1.33 for 6-month continuous abstinence according
to intention-to-treat). The overall strongest predictor in the adjusted analyses was smoking status in the week
before baseline (OR 3.30, 95% CI 1.79–6.09 for point prevalence and OR 3.97, 95% CI 2.01–7.83 for 6-month
continuous abstinence).
Conclusions: The perceived ability to handle stress and depressive mood without smoking at baseline predicted
the subjects’ abstinence at the 12-month follow-up. An assessment of/adjustment for stress and depressive mood
coping skills may be appropriate in future smoking cessation treatment and research. The treatment protocol can
be tailored to individual differences and needs for optimal support.
Trial registration: ClinicalTrials.gov: NCT02085616. Registered March 10, 2014, ‘retrospectively registered’.
Keywords: Depressive mood, Point prevalence, Self-efficacy, Self-perceived abilities, Single-item assessment, 6-month
continuous abstinence, Tobacco
* Correspondence: eva.nohlert@regionvastmanland.se
1Centre for Clinical Research, Uppsala University, Hospital of Vastmanland
Vasteras, 721 89 Vasteras, Sweden
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Nohlert et al. BMC Public Health  (2018) 18:1066 
https://doi.org/10.1186/s12889-018-5973-9
Background
Tobacco smoking is still one of the leading risk factors
for early death and morbidity and is projected to kill
more than eight million people per year by 2030 [1].
Non-communicable diseases (NCDs) are increasing
worldwide and caused 40 million deaths in 2015 [2]. To-
bacco smoking is a major cause of many NCDs and con-
tributed to almost 150 million global disability-adjusted
life-years (DALYs) in 2015 [3].
There is sound evidence for the efficacy of interventions
and strategies to reduce tobacco consumption [4–7].
However, it is important to understand which factors are
associated with quitting success for improving the efficacy
of the interventions. Among smoking cessation therapies,
telephone-based smoking cessation services (‘quitlines’)
are both effective and cost-effective [7–12]. Knowledge of
modifiable baseline factors in real-life settings with hetero-
geneous participants is essential for the development and
improvement of treatment protocols in telephone-based
smoking cessation.
Commonly reported predictors for successful quitting
include high motivation, low nicotine dependence/low
number of cigarettes smoked per day, high socio-economic
status, social support, number and length of previous quit
attempts, high self-efficacy to quit, low stress level, and no
psychiatric comorbidity [7, 13, 14]. Intention to quit has
been shown to predict quitting attempt [15–17]. In a
review from 2011, the authors found motivational factors
(such as intention to quit or wish to quit) to be associated
with quitting attempts, but not consistently associated with
maintaining abstinence [14]. Stress and depressive mood
have also been associated with smoking behaviour and the
ability to quit smoking in several studies [18–21]. In a pre-
vious prospective study using epidemiological methods at
the Swedish National Tobacco Quitline (SNTQ), the
authors found that clients who experienced periods of de-
pressive mood and/or periods of stress after their first
contact with SNTQ were less likely to be smoke-free at
follow-up [13]. Thus, perceived ability to handle stress and
depressive mood without smoking could be a predictor of
quitting that may be modifiable during the treatment. In a
RCT from 2014, the authors found that a stress and anger
management programme significantly enhanced smoking
cessation rates [22].
Self-efficacy, confidence in perceived ability to quit
smoking and conceivable strategies to handle different
situations without smoking, have been of interest for
tobacco cessation research. High self-efficacy to quit
smoking has been shown to predict successful quitting
[23–27] but research on different aspects of self-efficacy
and smoking cessation in a quitline setting is limited. In
a randomized controlled trial (RCT) of quitline counsel-
ling versus the use of a self-help brochure for smoking
parents, increased self-efficacy to refrain from smoking
in stressful and tempting situations, and increased ac-
ceptance of craving to smoke significantly mediated the
effect of smoking cessation counselling on prolonged
abstinence at a 12-month follow-up with an explained vari-
ance of 25.1% [28]. One study found that low self-efficacy
to quit smoking could predict relapse during 6 months
after calling a quitline [29]. However, a meta-analysis from
2009 [30] found the association between self-efficacy and
smoking abstinence to be greatly reduced when controlling
for smoking status at the time of the assessment of the
clients’ perceived ability to stop smoking.
The SNTQ was established in 1998 and is a free
nationwide service operated by the Stockholm County
Council Health Service and funded by the Swedish
Government. In previous studies at the SNTQ, point
prevalence abstinence rates have gradually increased from
28% to approximately 40%, using the definition of the
study base as those responding to a baseline questionnaire
[11, 13, 31]. The treatment protocol is a mixture of motiv-
ational interviewing, cognitive behaviour therapy, and
pharmacological consultation. It has been a step-by-step
process to identify modifiable baseline factors associated
with quitting and to integrate them into the SNTQ support
protocol [11, 13, 31].
In the present study we aimed to assess aspects of
self-perceived abilities that may potentially be affected
during treatment, and their relationship to successful
cessation at 12-month follow-up at the SNTQ. We
assessed i) self-perceived ability to quit smoking and ii)
self-perceived ability to cope with stress and depressive
mood without smoking. The rational for assessing these
two aspects is mainly based on our clinical experience and
our previous studies [13]. We do not claim to be using
psychometrically validated methods to measure “self--
efficacy”. However, the methodology used to assess
self-perceived abilities in the present study is similar to that
used to assess self-efficacy, which originates from Social
Cognitive Theory [32]. Thus, we deem it appropriate to
discuss our results in the context of self-efficacy research.
We hypothesized that high scores on clients’ own
self-perceived ability to cope at baseline would predict
abstinence at a 12-month follow-up. We tested this hy-
pothesis for two different aspects of self-perceived ability
to cope at baseline: (1) the likelihood of being smoke-free
in 1 year and (2) the perceived ability to handle stress and
depressive mood without smoking.
Methods
Standard SNTQ process
All calls to the SNTQ are registered in a computerized
database. When a tobacco user calls to discuss his/her
personal tobacco behaviour, the counsellor asks whether
the client would like to sign up for cessation support. If
the client gives verbal consent, their preference for
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call-back (proactive service) or no call-back (reactive ser-
vice) is recorded, and a registration form including the
baseline questionnaire, is mailed to them. The return of
the baseline questionnaire is regarded as informed
consent and the client is included in a study base to
assess effectiveness. Twelve months after the first call, a
follow-up questionnaire is sent by mail to the client.
Non-responders to the follow-up questionnaire receive
up to two reminders, one by mail, and one by telephone.
The SNTQ and the counselling process have been
described previously [11, 13, 31].
Study population
The study was performed as part of the normal operation
at the SNTQ, during a 20-month period in 2009–2010
when a RCT was carried out, with the primary aim to as-
sess the effectiveness of the proactive versus the reactive
service [11]. Thus, the clients were randomized to pro-
active or reactive services instead of being offered a
choice. We included all clients recruited for tobacco
cessation support at the quitline from February 2009
to September 2010. During that period, a total of 1212
calls were classified as new treatment calls. Snus (moist
snuff) cessation calls were excluded, leaving 1129 in the
study population. Those 612 subjects who returned the
baseline questionnaire constituted the study base and
were included in the Intention-To-Treat (ITT) analyses.
The 359 who returned the follow-up questionnaire were
included in responder-only analyses (Fig. 1).
Questions and outcome measures
Baseline self-perceived ability to cope was assessed
through two different questions: (1) ‘How likely is it that
you will be completely smoke-free in one year?’ and (2)
‘I can handle stress and depressive mood without smok-
ing’. The participants were asked to rate themselves on a
numeric rating scale from 1= ‘not at all likely’ to 10 = ‘very
likely’. To determine whether the response alternatives
Fig. 1 Flow chart of the study. * ITT, intention-to-treat † Internal drop-out for outcome variables in the follow-up questionnaire for one individual
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should be treated as numerical values or grouped/dichoto-
mized, we analysed the proportion of quitters within each
of the 10 steps in the scales and then plotted the results.
We found nothing that supported a grouping/dichotomi-
zation, so the two self-perceived ability to cope questions
were treated as numerical variables.
Abstinence at 12-month follow-up was assessed
through two questions: (1) ‘Have you smoked (one or
more deep drags) during the past 7 days?’ with response
options of ‘no, not at all’, ‘yes, but not daily’, and ‘yes
daily’; and (2) ‘When did you take your last puff?’ with
response options of ‘0–7 days ago’, ‘more than 7 days but
less than 6 months ago’, ‘6–12 months ago’, and ‘more
than 12 months ago’. Outcome measures were point
prevalence abstinence (not a puff in the previous 7 days)
and 6-month continuous abstinence (not a puff in the
previous 6 months) at the 12-month follow-up.
Additional questions comprised items about the daily
consumption of cigarettes, snus, and tobacco cessation
medication, different aspects of present and previous
smoking habits and quitting attempts, willingness to use
evidence based medication to overcome craving, expos-
ure to second-hand smoke, and access to other support
(social, professional).
The study was approved by the Ethics Committee at
Karolinska Institutet (Dnr 00–367).
Data analysis
IBM SPSS Statistics (version 24; IBM Corp., Armonk,
NY, USA) was used to conduct the statistical analyses
and p < 0.05 (two-sided) was considered statistically
significant. Spearman’s rank correlation coefficient (rho)
was calculated to assess any association between the two
variables measuring self-perceived ability to cope. Logis-
tic regression analysis was performed to calculate odds
ratios (ORs) with 95% confidence intervals (CIs) for the
two abstinence measures. Univariable analyses were per-
formed for all relevant independent baseline variables.
Established confounders described in the literature (gen-
der, number of smoked cigarettes/day, smoking status at
baseline, socio-economic status measured as education
level, exposure to passive smoking, pharmaceutical use,
snus use, and any other support) and the two self-perceived
ability to cope variables were included in the multivariable
analyses. The proportion of total variability explained by
the model was assessed by Nagelkerke’s R2. The Hosmer
and Lemeshow goodness-of-fit test was used to test the
overall fit of the logistic regression model [33].
Results
Baseline characteristics of the study population are listed
in Table 1. Fifty-nine per cent (359/612) responded to
the 12-month follow-up questionnaire. At the 12-month
follow-up, the self-reported responders-only point preva-
lence abstinence was 46% (166/358) and the 6-month con-
tinuous abstinence rate was 35% (126/358) (Table 2).
Results from the univariable logistic regression ana-
lyses are presented in Tables 3 and 4. The two baseline
variables used to assess self-perceived ability to cope, the
likelihood of being smoke-free in 1 year and perceived
Table 1 Population characteristics at baseline
Total Responders Non-responders
Gender: women (% n/N) 77 (474/612) 77 (278/359) 77 (196/253)
Age groups, years (% n/N)
≤ 34 20 (122/602) 16 (57/352) 26 (65/250)a
35–49 25 (150/602) 24 (85/352) 6 (65/250)
50–64 38 (231/602) 41 (146/352) 34 (85/250)
≥ 65 16 (99/602) 18 (64/352) 14 (35/250)
Number of years of education (md, q1-q3, N) 12, 10–13, 594 12, 9–14, 355 12, 10–13, 239
Number of smoked cigarettes/day (data journal) (md, q1-q3, N) 10, 0–20, 505 8, 0–15, 297 11, 3–20, 208a
No smoking in the week before baseline (% n/N) 28 (171/609) 34 (121/359) 20 (50/250)a
Number of years smoked before baseline (md, q1-q3, N) 32, 17–40, 575 35, 20–43, 344 30, 15–40, 231a
Snus use the week before baseline (% n/N) 7 (38/552) 6 (18/318) 9 (20/234)
Exposed to passive smoking (baseline) (% n/N) 26 (147/573) 22 (74/336) 31 (73/237) a
Drug use (NRT, Zyban®, Champix®) the week before baseline (% n/N) 52 (308/592) 57 (198/349) 45 (110/243) a
Other support at baseline (% n/N) 71 (428/600) 73 (254/349) 69 (174/251)
Likelihood of being smoke-free in 1 year (baseline, 1–10) (md, q1-q3, N) 8, 7–10, 590 9, 7–10, 347 8, 7–10, 243
Handle stress and depression successfully without smoking (baseline, 1–10) (md, q1-q3, N) 7, 4–9, 590 7, 4–9, 346 6, 4–8, 244 a
Will use pharmaceuticals if necessary (baseline,1–10) (md, q1-q3, N) 10, 5–10, 592 10, 5–10, 348 9, 5–10, 244
aStatistically significant difference between responders and non-responders. Tested by Chi-2/Fisher’s Exact test or Mann-Whitney U-test
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ability to handle stress and depressive mood without
smoking were both significant predictors for abstinence.
These two self-perceived ability to cope variables
were relatively strongly correlated (Spearman’s rho 0.522,
p < 0.001). However, only the perceived ability to handle
stress and depressive mood without smoking remained
significant for abstinence at month 12 in the adjusted
analyses, with an OR of 1.13 for point prevalence and
1.16 for 6-month continuous abstinence according to
ITT (Table 5). The overall strongest predictor for ab-
stinence in the adjusted analyses was smoking status in
the week before baseline, with an OR of 3.30 for point
prevalence and 3.97 for 6-month continuous abstinence
(Table 5).
Discussion
The participants’ perceived ability to handle stress and
depressive mood without smoking at baseline predicted
abstinence at the 12-month follow-up when adjusted for
all potential confounders. However, the likelihood of
being smoke-free in 1 year did not.
As in previous studies, the strongest predictor for ab-
stinence at the 12-month follow-up was smoking status
in the week before baseline, a variable that can serve as
a proxy for motivation as well as dependence [7, 13, 14].
A systematic review reported that motivational factors
dominate the prediction of quit attempts, but that only
cigarette dependence consistently predicts the success of
those attempts in adult general populations [14] . Similar
findings are reported from the International Tobacco
Control Four Country Survey [15] and from the AT-
TEMPT cohort study [17]. One study reported that de-
pendence, but not motivation, predicted abstinence in a
clinical sample of smokers seeking help to quit [34].
Self-efficacy research, using similar scales as in the
present study, has been associated with smoking abstin-
ence in numerous studies [23–26, 28–30, 35–39]. Two
multi-item self-efficacy measures¸ the “Smoking Abstin-
ence Self-Efficacy Scale” [40] and the “Smoking Self-Effi-
cacy Questionnaire” [41], have been frequently used in
smoking cessation studies [25, 28, 36, 38]. Generally,
multi-item measures are likely to be more reliable and
valid than single-item measures in assessing different
constructs. However, in one meta-analysis, the authors
did not find support for their hypothesis that the asso-
ciation between self-efficacy and smoking cessation
would be moderated by the number of items measuring
self-efficacy [30].
We assessed two aspects of self-perceived ability to
cope using single-item questions with response alterna-
tives from 1 to 10 on a numeric rating scale. The items
were aimed at assessing a specific situation during a
specific period [32]. The perceived likelihood of being
smoke-free in 1 year and perceived ability to handle
stress and depressive mood without smoking were both
statistically significant predictors of successful smoking
cessation in the univariable analyses. However, in the
multivariable analyses, only the participants’ perceived
ability to handle stress and depressive mood without
smoking remained significant (when adjusted for all
potential confounders).
A single-item measure, ‘How confident are you that
you will be able to quit for good at this time?’ on a
5-point scale was a reliable predictor of relapse in an
Australian quitline study [29]. Lindberg et al. who used a
single-item question, ‘How confident are you that you
will succeed if you decide to quit?’, and a 10-point scale
in a study of smoking patients with chronic obstructive
pulmonary disease (COPD), found it to be a valuable
instrument for predicting smoking cessation over several
years [37]. Hendricks et al. also used a single-item ques-
tion to measure self-efficacy as a predictor for abstinence
in a RCT of a cognitive behavioural smoking cessation
intervention among treatment-seeking smokers [24].
They asked the smokers to indicate on a 10-point scale
how successful they expected to be in quitting.
Because of the clinical setting in our study, we deemed
it more feasible to use single-item questions. We further
discuss the single-item assessment below, under the
heading ‘Strengths and limitations’.
Since the questions were only asked on one occasion,
we could not assess whether changes in self-perceived
abilities over time affected the progression of abstinence
rates. However, in the multivariable analyses we con-
trolled for the baseline smoking status. This is an im-
portant issue, because those who have already managed
to quit on their own before calling the quitline could be
expected to have a higher belief in their own ability to
quit [30]. Intention and perceived ability to quit are
dynamic factors and consequently predicting smoking
cessation based on these factors can be difficult.
Self-efficacy and intention to quit vary over time, even
Table 2 Point prevalence and 6-month continuous abstinence at 12-month follow-up






Responder-only 46.4 (166/358) 35.2 (126/358) 37.1 28.2
Intention to treata 27.1 (166/612) 20.6 (126/612) 21.7 16.5
a Non-responders at 12-month follow-up treated as smokers
bAccording to a proposed conservative correction factor of 0.8 for self-reported abstinence based on a non-response analysis at the SNTQ [47]
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daily [23, 42, 43] and tend to differ between studies
[16, 42, 44].
The timing of self-perceived ability assessment can be
important. The relationship between self-efficacy and
future smoking has been reported to be weaker when
self-efficacy is assessed prior to a quit attempt and stron-
ger when assessed after the subjects have quit smoking
[30]. The authors of that meta-analysis concluded that
Table 3 Univariable logistic regression analyses for responders-only point prevalence and 6-month continuous abstinence
Point prevalence abstinence
Variable n/Na OR (95% CI for OR) p
Gender; men vs. women (ref) 81/358 vs. 277/358 0.53 (0.32–0.89) 0.016
Age, years 0.077
- ≤ 34 (ref) 57/351 1.0
- 35-49 85/351 1.22 (0.62–2.39) 0.559
- 50-64 145/351 0.94 (0.51–1.74) 0.844
- ≥ 65 64/351 0.51 (0.24–1.06) 0.070
Number of smoked cigarettes/day (data journal) md = 8, q1 = 0, q3 = 15, N = 296 0.94 (0.92–0.97) < 0.001
Variables from baseline questionnaire
Number of years of education md = 12, q1 = 9, q3 = 14, N = 354 1.07 (0.99–1.16) 0.067
Number of years smoked before baseline md = 35, q1 = 20, q3 = 43, N = 343 0.99 (0.97–1.00) 0.076
Smoking the week before baseline; no vs. yes (ref) 121/358 vs. 237/358 4.29 (2.68–6.87) < 0.001
Passive smoking at baseline; not exposed vs. exposed (ref) 261/335 vs. 74/335 1.37 (0.81–2.31) 0.240
Drug use (NRT, Zyban®, Champix®) the week before baseline; yes vs. no (ref) 197/348 vs. 151/348 1.48 (0.97–2.27) 0.073
Snus use the week before baseline; yes vs. no (ref) 18/317 vs. 299/317 0.41 (0.14–1.19) 0.102
Other support at baseline: yesb vs. no (ref) 254/348 vs. 94/348 1.79 (1.10–2.92) 0.019
Likelihood of being smoke-free in 1 year (baseline, 1–10) md = 9, q1 = 7, q3 = 10, N = 346 1.26 (1.13–1.41) < 0.001
Handle stress and depression successfully without smoking (baseline, 1–10) md = 7, q1 = 4, q3 = 9, N = 345 1.22 (1.13–1.33) < 0.001
Will use pharmaceuticals if necessary (baseline,1–10) md = 10, q1 = 5, q3 = 10, N = 347 0.98 (0.91–1.04) 0.476
6-month continuous abstinence
Variable n/Na OR (95% CI for OR) p
Gender; men vs. women (ref) 81/358 vs. 277/358 0.62 (0.36–1.07) 0.087
Age, years 0.070
- ≤ 34 (ref) 57/351 1.0
- 35-49 85/351 1.50 (0.75–2.99) 0.254
- 50-64 145/351 1.00 (0.53–1.91) 0.991
- ≥ 65 64/351 0.57 (0.26–1.25) 0.160
Number of smoked cigarettes/day (data journal) md = 8, q1 = 0, q3 = 15, N = 296 0.94 (0.91–0.97) < 0.001
Variables from baseline questionnaire
Number of years of education md = 12, q1 = 9, q3 = 14, N = 354 1.06 (0.98–1.15) 0.145
Number of years smoked before baseline md = 35, q1 = 20, q3 = 43, N = 343 1.00 (0.98–1.01) 0.572
Smoking the week before baseline; no vs. yes (ref) 121/358 vs. 237/358 5.28 (3.28–8.49) < 0.001
Passive smoking at baseline; not exposed vs. exposed (ref) 261/335 vs. 74/335 1.87 (1.04–3.37) 0.037
Drug use (NRT, Zyban®, Champix®) the week before baseline; yes vs. no (ref) 197/348 vs. 151/348 1.28 (0.82–2.00) 0.278
Snus use the week before baseline; yes vs. no (ref) 18/317 vs. 299/317 0.21 (0.05–0.93) 0.039
Other support at baseline: yesb vs. no (ref) 254/348 vs. 94/348 1.53 (0.92–2.56) 0.103
Likelihood of being smoke-free in 1 year (baseline, 1–10) md = 9, q1 = 7, q3 = 10, N = 346 1.39 (1.21–1.59) < 0.001
Handle stress and depression successfully without smoking (baseline, 1–10) md = 7, q1 = 4, q3 = 9, N = 345 1.29 (1.18–1.41) < 0.001
Will use pharmaceuticals if necessary (baseline,1–10) md = 10, q1 = 5, q3 = 10, N = 347 0.96 (0.90–1.03) 0.264
a n = number in category, N = total number in analysis
b Social and/or professional support
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Table 4 Univariable logistic regression analyses for point prevalence and 6-month continuous abstinence, including non-responders
at follow-up treated as smokers
Point prevalence abstinence
Variable n/Na OR (95% CI for OR) p
Gender; men vs. women (ref) 138/612 vs. 474/612 0.62 (0.39–0.98) 0.041
Age, years 0.203
- ≤ 34 (ref) 122/602 1.0
- 35-49 150/602 1.49 (0.86–2.56) 0.156
- 50-64 231/602 1.43 (0.86–2.37) 0.167
- ≥ 65 99/602 0.90 (0.48–1.71) 0.757
Number of smoked cigarettes/day (data journal) md = 10, q1 = 0, q3 = 20, N = 505 0.94 (0.91–0.96) < 0.001
Variables from baseline questionnaire
Number of years of education md = 12, q1 = 10, q3 = 13, N = 594 1.05 (0.99–1.12) 0.116
Number of years smoked before baseline md = 32, q1 = 17, q3 = 40, N = 575 1.00 (0.99–1.01) 0.957
Smoking the week before baseline; no vs. yes (ref) 171/609 vs. 438/609 4.19 (2.85–6.15) < 0.001
Passive smoking at baseline; not exposed vs. exposed (ref) 426/573 vs. 147/573 1.64 (1.04–2.57) 0.032
Drug use (NRT, Zyban®, Champix®) the week before baseline; yes vs. no (ref) 308/592 vs. 284/592 1.72 (1.19–2.49) 0.004
Snus use the week before baseline; yes vs. no (ref) 38/552 vs. 514/552 0.39 (0.15–1.02) 0.054
Other support at baseline: yesb vs. no (ref) 428/600 vs. 172/600 1.73 (1.13–2.66) 0.012
Likelihood of being smoke-free in 1 year (baseline, 1–10) md = 8, q1 = 7, q3 = 10, N = 590 1.23 (1.11–1.36) < 0.001
Handle stress and depression successfully without smoking (baseline, 1–10) md = 7, q1 = 4, q3 = 9, N = 590 1.22 (1.13–1.31) < 0.001
Will use pharmaceuticals if necessary (baseline,1–10) md = 9, q1 = 5, q3 = 10, N = 592 0.99 (0.93–1.04) 0.624
6-month continuous abstinence
Variable n/Na OR (95% CI for OR) p
Gender; men vs. women (ref) 138/612 vs. 474/612 0.67 (0.41–1.12) 0.127
Age, years 0.144
- ≤ 34 (ref) 122/602 1.0
- 35-49 150/602 1.73 (0.95–3.17) 0.075
- 50-64 231/602 1.45 (0.82–2.56) 0.207
- ≥ 65 99/602 0.91 (0.44–1.89) 0.801
Number of smoked cigarettes/day (data journal) md = 10, q1 = 0, q3 = 20, N = 505 0.93 (0.91–0.96) < 0.001
Variables from baseline questionnaire
Number of years of education md = 12, q1 = 10, q3 = 13, N = 594 1.05 (0.98–1.12) 0.188
Number of years smoked before baseline md = 32, q1 = 17, q3 = 40, N = 575 1.01 (0.99–1.02) 0.423
Smoking the week before baseline; no vs. yes (ref) 171/609 vs. 438/609 5.41 (3.56–8.21) < 0.001
Passive smoking at baseline; not exposed vs. exposed (ref) 426/573 vs. 147/573 2.14 (1.25–3.68) 0.006
Drug use (NRT, Zyban®, Champix®) the week before baseline; yes vs. no (ref) 308/592 vs. 284/592 1.54 (1.03–2.31) 0.035
Snus use the week before baseline; yes vs. no (ref) 38/552 vs. 514/552 0.20 (0.05–0.84) 0.028
Other support at baseline: yesb vs. no (ref) 428/600 vs. 172/600 1.57 (0.99–2.52) 0.058
Likelihood of being smoke-free in 1 year (baseline, 1–10) md = 8, q1 = 7, q3 = 10, N = 590 1.35 (1.19–1.53) < 0.001
Handle stress and depression successfully without smoking (baseline, 1–10) md = 7, q1 = 4, q3 = 9, N = 590 1.29 (1.19–1.41) < 0.001
Will use pharmaceuticals if necessary (baseline,1–10) md = 9, q1 = 5, q3 = 10, N = 592 0.97 (0.91–1.03) 0.365
a n = number in category, N = total number in analysis
b Social and/or professional support
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controlling for smoking status at the time of the
self-efficacy assessment substantially reduced the relation-
ship. In a study of smoking parents in the Netherlands, in-
creased self-efficacy to refrain from smoking in stressful
and tempting situations significantly mediated the effect
of quitline cessation counselling on prolonged abstinence
at a 12-month follow-up. In that study, self-efficacy was
assessed at 3 months post-measurement. The authors
concluded that the effect could be a result of quitting
rather than a mechanism that contributed to it [28].
Strengths and limitations
Using single items has been criticized for a lack of sensi-
tivity [32], and we acknowledge this methodological prob-
lem. However, both items actually predicted abstinence in
the univariable analyses and one item remained statisti-
cally significant in the multivariable analyses.
In the present study, the self-perceived ability questions
were asked on one occasion, in the baseline questionnaire
to which the clients responded within 7 days after their
first call to the quitline. Consequently, we cannot com-
ment on possible changes in self-perceived ability during
treatment and its possible relation to quit rates, which is a
limitation. However, we asked for smoking status at the
same time as self-perceived ability was assessed, which
probably is a strength of the study.
The double-barrel nature of the stress/depressive
mood question warrants caution. Although the question
did predict smoking cessation outcome in its present
form, we do not know whether assessing belief in ability
to handle stress versus depressive mood separately might
affect the outcome differently. Therefore, additional
research is necessary to discover the potential independ-
ent predictive value of self-efficacy/self-perceived ability
for ‘handling stress’ versus ‘handling depressive mood’
using single-item assessment.
Nicotine dependence is a sound predictor for success-
ful quitting [14]. In the present study, we only obtained
information on one of the two most important measures
of dependence, namely, the number of smoked cigarettes
per day at baseline, not the time to the first cigarette in
the morning, which is a potential limitation.
The study was performed within the normal running
activity at the SNTQ, and thus under real-world condi-
tions, which might be a strength for generalizability.
However, the results may be limited to Swedish-speaking
smokers seeking treatment. Obviously, the response rate
of only 59% at the 12-month follow-up is a limitation to
the analysis. Although relatively normal for studies like
this [45] it might be a potential source of bias. We
attempted to control for this by comparing the propor-
tion of smokers at baseline among the responders versus
non-responders. The proportion of smokers was signifi-
cantly higher among non-responders (80%) than re-
sponders (66%) (p < 0.001). Non-responders were also
younger, more exposed to passive smoking, were less likely
to use tobacco cessation medication (Nicotine Replace-
ment Therapy (NRT), bupropion (e.g. Zyban®), varenicline
(Champix®)), and had lower scores on ability to handle
stress and depressive mood without smoking, than were
responders (Table 1). A conservative way to handle a rela-
tively low response rate is to report the non-responders as
still smokers in a separate analysis together with the
responder-only analyses. We thus publish both analyses.
Table 5 Multivariable logistic regression analysesa for point prevalence abstinence and 6-month continuous abstinence
N = 214 Responders-only
Variable Point prevalence abstinenceb 6-month continuous abstinencec
OR (95% CI) p OR (95% CI) p
Likelihood of being smoke-free in 1 year 1.00 (0.84–1.19) 0.985 1.04 (0.85–1.27) 0.695
Perceived ability to handle stress and depressive mood without smoking 1.18 (1.03–1.36) 0.017 1.20 (1.03–1.39) 0.020
Smoked in the week before baseline (ref. = yes) 3.28 (1.58–6.81) 0.001 3.93 (1.86–8.31) < 0.001
N = 362 Including non-responders at follow-up (treated as smokers)
Variable Point prevalence abstinenced 6-month continuous abstinencee
OR (95% CI) p OR (95% CI) p
Likelihood of being smoke-free in 1 year 1.02 (0.88–1.19) 0.762 1.05 (0.88–1.25) 0.570
Perceived ability to handle stress and depressive mood without smoking 1.13 (1.00–1.27) 0.050 1.16 (1.01–1.33) 0.033
Smoked in the week before baseline (ref. = yes) 3.30 (1.79–6.09) < 0.001 3.97 (2.01–7.83) < 0.001
Variables shown in the table are the two self-perceived ability to cope variables and statistically significant variables
aIncluded variables: gender, age, number of cigarettes/day, number of years of education, number of years smoked, smoking in the week before baseline, passive
smoking, drug use, snus use, other support, likelihood of being smoke-free in 1 year, handle stress and depressive mood without smoking, and willingness to
use pharmaceuticals
bNagelkerke R2 26.1%. Hosmer and Lemeshow test of goodness of fit, p = 0.356
cNagelkerke R2 28.2%. Hosmer and Lemeshow test of goodness of fit, p = 0.202
dNagelkerke R2 21.5%. Hosmer and Lemeshow test of goodness of fit, p = 0.193
eNagelkerke R2 24.5%. Hosmer and Lemeshow test of goodness of fit, p = 0.914
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Self-reported smoking cessation assessment may also
potentially affect the validity of the outcome assessment
in all smoking cessation studies. Yet, biochemical verifica-
tion is not required and may not be desirable in studies
where the optimal data collection methods are through
mail, telephone, or the Internet [46]. Also, it is unlikely
that the proportion of false positives would be different
for different self-efficacy levels at baseline.
Potential application of the present findings to the quitline
protocol
At present the questions of self-perceived ability to cope
are included in the baseline questionnaire. As it is theoret-
ically possible to influence self- perceived ability to cope,
it could be a benefit to assess the clients’ self-perceived
ability to cope/self-efficacy already at the first call and
adapt the support accordingly.
Conclusions
Perceived ability to handle stress and depressive mood
without smoking at baseline predicted abstinence at the
12-month follow-up. According to the results, an assess-
ment of/adjustment for stress and depressive mood cop-
ing skills may be appropriate in future smoking cessation
treatment and research. The treatment protocol can be
tailored to individual differences and needs for optimal
support.
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